AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3320366
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg twice daily
Trial: 28475703
Drug: Cibinetide 1
RxNorm normalized name: Cibinetide
DrugBank: Cibinetide (DB13006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibinetide 1 mg/day
Trial: 28475703
Drug: Cibinetide 4
RxNorm normalized name: Cibinetide
DrugBank: Cibinetide (DB13006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibinetide 4 mg/day
Trial: 28475703
Drug: Cibinetide 8
RxNorm normalized name: Cibinetide
DrugBank: Cibinetide (DB13006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibinetide 8 mg/day
Trial: 25512031
Drug: Bupivacaine (0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.25% solution with adrenaline) alone
Trial: 22585373
Drug: Miconazole nitrate
RxNorm normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole nitrate oral disintegrating tablets (specific formulation details: magnesium stearate as lubricant, hydrophobic Aerosil R972 as glidant, low urea content, mannitol/microcrystalline cellulose ratio 2:1, and 9% Plasdone XL100 as superdisintegrant)
Trial: 11844850
Drug: Vaccine with
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine with S. aureus type 5 and 8 capsular polysaccharides conjugated to nontoxic recombinant Pseudomonas aeruginosa exotoxin A
Trial: 26781281
Drug: Taurine supplementation
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine supplementation (1.6 g per day)
Trial: 18715950
Drug: Motexafin gadolinium
RxNorm normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motexafin gadolinium (MGd) at doses of 1.7 to 9.2 mg/kg daily prior to radiation therapy for 6 weeks
Trial: 18715950
Drug: Motexafin gadolinium
RxNorm normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motexafin gadolinium (MGd) administered as a 5-min intravenous bolus 2-5 h prior to standard radiation therapy
Trial: 18715950
Drug: Involved field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved field radiation therapy administered to 54 Gy in 30 once-daily fractions
Trial: 14975200
Drug: HRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT plus fluoxetine
Trial: 11700394
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of rhAPC (12, 18, 24, or 30 microg/kg/hr) for 48 or 96 hrs
Trial: 22901887
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg three times a week for 6 months
Trial: 8023546
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (Havrix) stored at 37 degrees C for 1 week
Trial: 3531295
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg twice daily
Trial: 30057745
Drug: GM604 (compassionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM604 (compassionate treatment)
Trial: 26531865
Drug: Suboptimal SCIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suboptimal SCIT (30,000 standardized quality units) plus placebo antibody
Trial: 26531865
Drug: Double placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double placebo (placebo SCIT and placebo antibody)
Trial: 23022391
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Ze 440
Trial: 23022391
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Ze 440
Trial: 23022391
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg Ze 440
Trial: 15302290
Drug: Optimal surgical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal surgical treatment plus adhesion barrier (SprayGel)
Trial: 15302290
Drug: Optimal surgical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal surgical treatment alone
Trial: 8580980
Drug: Moxisylyte 10
RxNorm normalized name: moxisylyte
DrugBank: Moxisylyte (DB09205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxisylyte 10 mg
Trial: 8580980
Drug: Moxisylyte 20
RxNorm normalized name: moxisylyte
DrugBank: Moxisylyte (DB09205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxisylyte 20 mg
Trial: 8580980
Drug: Moxisylyte 30
RxNorm normalized name: moxisylyte 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxisylyte 30 mg
Trial: 772817
Drug: Azathioprine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (50 to 175 mg/day)
Trial: 14969665
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (OC)
Trial: 12114886
Drug: Duloxetine 40
RxNorm normalized name: duloxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 40 mg/day
Trial: 15488162
Drug: Washing of
RxNorm normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Washing of the CVP using normal saline solution before each closure and every 6 hours
Trial: 15488162
Drug: Closure of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closure of the CVP using an obturator after the suspension of the infused therapy
Trial: 11201509
Drug: Estrogen (Premarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen (Premarin 0.625 mg) and medroxyprogesterone acetate (Provera 5 mg)
Trial: 21073640
Drug: Make A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Make A Difference about Art programme (art therapy intervention)
Trial: 11905780
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy for advanced laryngeal cancer
Trial: 11905780
Drug: Chemotherapy given
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy given concomitantly with radiotherapy
Trial: 9737645
Drug: Cerivastatin 0.025-0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.025-0.4 mg/day
Trial: 9737644
Drug: Cerivastatin (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin (higher doses)
Trial: 9737644
Drug: Cerivastatin (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin (long-term administration)
Trial: 7536025
Drug: G-CSF (Filgrastim)
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (Filgrastim) 300 microgram s.c. daily
Trial: 2665058
Drug: Insulin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (7.5 U fast-acting insulin/kg b.w. as a bolus followed by continuous infusion of 15 U/kg b.w. for 1 hour)
Trial: 2665058
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no insulin treatment)
Trial: 29966016
Drug: Non-administration group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-administration group
Trial: 16984757
Drug: Stimulated cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulated cycles with recombinant FSH and human gonadotrophin hormone injection
Trial: 9493920
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy with occasional hypnotics
Trial: 9493920
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy without hypnotics
Trial: 8348061
Drug: Isotretinoin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (10 mg/day)
Trial: 25730596
Drug: EX +
RxNorm normalized name: Freeflex + Transfer Adapter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX + SUPP (combined home‐based exercise and calcium and vitamin D supplements)
Trial: 25730596
Drug: SUPP (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUPP (calcium and vitamin D supplements alone)
Trial: 18163485
Drug: Atacicept (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept (70 mg, 210 mg, or 630 mg single doses; 3 doses of 70 mg, 3 doses of 210 mg, or 7 doses of 420 mg repeated doses)
Trial: 10805610
Drug: Cocaethylene (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaethylene (0.25 or 0.5 mg/kg)
Trial: 22076422
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (Group S)
Trial: 11336163
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement (both diets combined)
Trial: 11336163
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement (per-protocol analysis)
Trial: 3653859
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy (radiotherapy and chemotherapy)
Trial: 29973265
Drug: Acupuncture treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatments for 4 weeks
Trial: 31593273
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg of sprifermin administered every 12 months (n=110)
Trial: 31593273
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg of sprifermin administered every 6 months (n=111)
Trial: 31593273
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg of sprifermin administered every 12 months (n=110)
Trial: 31593273
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg of sprifermin (both dosing schedules)
Trial: 31593273
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg of sprifermin (both dosing schedules)
Trial: 19729375
Drug: Standard-dose lopinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose lopinavir/ritonavir
Trial: 19729375
Drug: Low-dose lopinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose lopinavir/ritonavir
Trial: 16566424
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry capsules (twice daily 500 mg)
Trial: 16566424
Drug: Oral lactobacilli
RxNorm normalized name: lactobacillic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lactobacilli (twice daily a capsule with > 10^9 colony-forming units of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14)
Trial: 16566424
Drug: Standardised antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised antibiotic therapy (once daily 480 mg trimethoprim-sulfamethoxazole)
Trial: 16566424
Drug: Standardised antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised antibiotic therapy
Trial: 8973673
Drug: 10.8-mg goserelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.8-mg goserelin acetate depot
Trial: 8973673
Drug: 3.6-mg goserelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6-mg goserelin acetate depot
Trial: 6363220
Drug: Pirenzepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (100 mg daily: 50 mg before breakfast and before evening meal)
Trial: 6363220
Drug: Cimetidine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1000 mg daily: 200 mg with breakfast, lunch, and evening meal, and 400 mg at bedtime)
Trial: 29734180
Drug: Ranibizumab (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (monthly regimen)
Trial: 22217510
Drug: Conventional-dose 17β-estradiol/norethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose 17β-estradiol/norethisterone acetate (NETA)
Trial: 22217510
Drug: Low-dose 17β-estradiol/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose 17β-estradiol/NETA
Trial: 20171140
Drug: Enalapril (EN)
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril (EN) 10 mg/day for 2 weeks, then 20 mg/day for 2 weeks
Trial: 8362431
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no warfarin)
Trial: 7572323
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplement (500 mg/day)
Trial: 7572323
Drug: Placebo (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mean calcium intake = 376 mg/day)
Trial: 7403330
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of dextrose and water with different magnesium, calcium, and potassium solutions
Trial: 31765657
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg testosterone gel
Trial: 7767193
Drug: Self medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self medication programme
Trial: 387230
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with L-PAM
Trial: 25185456
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus medication (nifedipine 5 mg once daily and beraprost 20 mg three times daily)
Trial: 27922194
Drug: Alprazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (1 mg)
Trial: 28482385
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii (250 mg/d) orally
Trial: 28482385
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antibiotic therapy and conventional treatment)
Trial: 21949219
Drug: Carbohydrate counting
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate counting applied to meal A (75 g carbohydrate)
Trial: 18035730
Drug: Meropenem (1.5-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1.5-3 g daily)
Trial: 18035730
Drug: Standard antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibacterial therapy (betalactams, fluoroquinolones, aminoglycosides, metronidazole)
Trial: 8233251
Drug: 40-minute dosing
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-minute dosing protocol (incremental dose 1.5 mU/minute until 7 mU/minute, then 1.5 or 3.0 mU/minute)
Trial: 8233251
Drug: 15-minute dosing
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-minute dosing protocol
Trial: 8233251
Drug: 40-minute dosing
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-minute dosing protocol
Trial: 3630857
Drug: Zinc picolinate
RxNorm normalized name: Zinc picolinate
DrugBank: Zinc picolinate (DB11175)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc picolinate (50 mg elemental zinc per day)
Trial: 3630857
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate (50 mg elemental zinc per day)
Trial: 3630857
Drug: Zinc citrate
RxNorm normalized name: Zinc Citrate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc citrate (50 mg elemental zinc per day)
Trial: 27806024
Drug: Cisplatin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (30 mg/m²) and 500,000 U IL-2 for 3 days
Trial: 18855271
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of trandolapril and verapamil (FDTV) 2/180 mg once a day
Trial: 18855271
Drug: Trandolapril (T)
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trandolapril (T) 2 mg once a day
Trial: 15889944
Drug: Phenytoin 100
RxNorm normalized name: phenytoin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin 100 mg, increased to 3 times daily (maximum 400 mg/day)
Trial: 15889944
Drug: Fluoxetine 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 7 mg, increased to 20 mg/day (3 times daily)
Trial: 8607241
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of 67.2 Gy
Trial: 8607241
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of 75.6 Gy
Trial: 31023381
Drug: Motherfit group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motherfit group therapy
Trial: 28138164
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block with bupivacaine 0.25% (0.50 ml/kg)
Trial: 28138164
Drug: Subcutaneous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous morphine (100 mcg/kg)
Trial: 28138164
Drug: Dorsal penile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsal penile nerve block with bupivacaine 0.25% (1 mg/kg)
Trial: 3088636
Drug: Binedaline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binedaline (100 mg)
Trial: 25973434
Drug: Bromocriptine, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine, 2.5 mg oral, twice a day for 14 days after delivery
Trial: 23172272
Drug: Allogeneic mesenchymal
RxNorm normalized name: Allogeneic mesenchymal precursor cell
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic mesenchymal stem cells (MSCs) - 100 × 10⁶ cells/infusion, 4 monthly infusions
Trial: 7648682
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 to 50 mg)
Trial: 7648682
Drug: Nifedipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (60 mg)
Trial: 27901214
Drug: Fluoxetine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine therapy (n=91)
Trial: 27901214
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (n=91)
Trial: 17803715
Drug: 600 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 micrograms oral misoprostol
Trial: 30691507
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy plus PCI
Trial: 27746061
Drug: Riociguat 0.5
RxNorm normalized name: riociguat 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat 0.5 mg (up-titrated to a maximum dose of 2.5 mg TID over 10 weeks)
Trial: 10598427
Drug: Manually controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually controlled infusion (MI group)
Trial: 1936477
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Glibenclamide added to Metformin)
Trial: 1936477
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Metformin added to Glibenclamide)
Trial: 6757152
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg mepindolol daily
Trial: 29540872
Drug: Conservative exercise
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative exercise therapy with Maitland thoracic manipulation
Trial: 18167405
Drug: Testosterone undecenoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecenoate 80 mg twice daily for 6 months
Trial: 20044683
Drug: Methylprednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (40 mg)
Trial: 10633486
Drug: Oral amphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amphetamine (30 mg)
Trial: 1394754
Drug: Rocuronium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.25 mg.kg‐1
Trial: 1394754
Drug: Rocuronium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.5 mg.kg‐1
Trial: 3915885
Drug: Tenoxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam (20 mg, 30 mg, 40 mg)
Trial: 3915885
Drug: Piroxicam (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (equivalent once-daily dosage)
Trial: 12834650
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of professional sessions attended during treatment
Trial: 12834650
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of GA meetings attended during treatment
Trial: 1958856
Drug: Beta-carotene 30
RxNorm normalized name: beta-carotene 30 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene 30 mg/day plus retinyl palmitate 25,000 IU/day
Trial: 31252655
Drug: Caffeine 3
RxNorm normalized name: caffeine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 3 mg/kg/b.m. (CAF‐3)